

MEDICARE ADVANTAGE PRIOR AUTHORIZATION REQUEST FORM

Adalimumab - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:	
Member Number:	Fax: Phone:	
Date of Birth:	Office Contact:	
Line of Business: Medicare Advantage	NPI: State Lic ID:	
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	
REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.		
Drug Name:		
Strength:		
Directions / SIG:		
Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.		
Q1. Will the patient be taking adalimumab concomitantly with another biologic Disease Modifying Anti-Rheumatic Drug (DMARD) or a targeted synthetic DMARD?		
☐ Yes	□ No	
Q2. Is this a reauthorization request?		
☐ Yes	□ No	
Q3. Is there confirmation of continued positive clinical response since starting the drug? If yes, go to 14.		
☐ Yes	□ No	
Q4. Are chart notes attached documenting a diagnosis of rheumatoid arthritis (RA) or juvenile idiopathic arthritis (JIA)?		
☐ Yes	□ No	



MEDICARE ADVANTAGE PRIOR AUTHORIZATION REQUEST FORM

Adalimumab - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:	
Q5. Has the patient had an inadequate response, intolerance, or contraindication to a trial of at least 1 conventional DMARD (e.g., methotrexate, hydroxychloroquine, leflunomide, sulfasalazine)?		
☐ Yes	□ No	
Q6. Are chart notes attached documenting a diagnosis of moderate to severe plaque psoriasis (PsO) and the patient is a candidate for systemic therapy or phototherapy?		
☐ Yes	□ No	
Q7. Has the patient had an inadequate response, intolerance or contraindication to 1 of the following: methotrexate, ultraviolet-B (UVB) therapy, or acitretin?		
☐ Yes	□ No	
Q8. Are chart notes attached documenting a diagnosis of Crohn's disease?		
☐ Yes	□ No	
Q9. Are chart notes attached documenting a diagnosis of hidradenitis suppurativa?		
☐ Yes	□ No	
Q10. Has the patient had an inadequate response, intolerance, or contraindication to at least one oral antibiotic (e.g., doxycycline, minocycline, amoxicillin-clavulanic acid, clindamycin, rifampin, dapsone)?		
☐ Yes	□ No	
Q11. Are chart notes attached documenting a diagnosis of uveitis?		
☐ Yes	□ No	
Q12. Has the patient had an inadequate response, intolerance, or contraindication to one or more of the following: A) oral or topical glucocorticoids (prednisone, methylprednisolone, prednisolone), B) immunosuppressive agents, or C) periocular or intraocular injection (triamcinolone)?		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



MEDICARE ADVANTAGE PRIOR AUTHORIZATION REQUEST FORM

Adalimumab - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:	
□Yes	□ No	
Q13. Are chart notes attached documenting an FDA-approved diagnosis not otherwise excluded from part D?		
□ Yes	□ No	
Q14. Is the drug being prescribed by or in consultation with an appropriate specialist such as a rheumatologist, dermatologist, gastroenterologist, or ophthalmologist?		
□Yes	□ No	
Q15. Requested Duration:		
☐ 12 Months	☐ Other:	
Q16. Additional Information:		
Prescriber Signature	Date	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

v2026